BIOCYTOGEN PHARMA. H YC1 - Asset Resilience Ratio

Latest as of June 2024: 0.35%

BIOCYTOGEN PHARMA. H YC1 (I54) has an Asset Resilience Ratio of 0.35% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore I54 total asset value for the complete picture of this company's asset base.

Liquid Assets

€8.62 Million

≈ $10.07 Million USD Cash + Short-term Investments

Total Assets

€2.43 Billion

≈ $2.84 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2023)

This chart shows how BIOCYTOGEN PHARMA. H YC1's Asset Resilience Ratio has changed over time. See how leveraged is BIOCYTOGEN PHARMA. H YC1's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down BIOCYTOGEN PHARMA. H YC1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see I54 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€8.62 Million	0.35%
Total Liquid Assets	€8.62 Million	0.35%

Asset Resilience Insights

Limited Liquidity: BIOCYTOGEN PHARMA. H YC1 maintains only 0.35% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

BIOCYTOGEN PHARMA. H YC1 Industry Peers by Asset Resilience Ratio

Compare BIOCYTOGEN PHARMA. H YC1's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	13.57%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	82.25%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%

Annual Asset Resilience Ratio for BIOCYTOGEN PHARMA. H YC1 (2021–2023)

The table below shows the annual Asset Resilience Ratio data for BIOCYTOGEN PHARMA. H YC1.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.35%	€8.49 Million ≈ $9.92 Million	€2.45 Billion ≈ $2.86 Billion	+0.05pp
2022-12-31	0.29%	€8.20 Million ≈ $9.58 Million	€2.80 Billion ≈ $3.27 Billion	-4.05pp
2021-12-31	4.34%	€100.00 Million ≈ $116.91 Million	€2.30 Billion ≈ $2.69 Billion	--

pp = percentage points

About BIOCYTOGEN PHARMA. H YC1

F:I54 Germany Biotechnology

Market Cap

$702.88 Million

€601.21 Million EUR

Market Cap Rank

#10834 Global

#1244 in Germany

Share Price

€5.60

Change (1 day)

+6.67%

52-Week Range

€1.81 - €6.90

All Time High

€6.90